Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

@article{Trarbach2011PhaseIO,
  title={Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours},
  author={Tanja Trarbach and Beate Schultheis and Thomas Christoph Gauler and Vesile Schneider and Dirk Strumberg and Wilfried Ernst Erich Eberhardt and St{\'e}phanie le Scouiller and Marcelo Marotti and Kathryn H. Brown and Joachim Drevs},
  journal={Investigational New Drugs},
  year={2011},
  volume={30},
  pages={1962-1971}
}
Combining different targeted anticancer agents may improve clinical outcomes. This Phase I study investigated cediranib, an oral inhibitor of vascular endothelial growth factor signalling in combination with saracatinib, an oral Src inhibitor. The primary endpoint was safety/tolerability. Secondary assessments included pharmacokinetics and preliminary efficacy. Patients and Methods Patients with advanced solid tumours received cediranib 20, 30 or 45 mg/day for 7 days followed by daily treatment… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 4 Excerpts
Highly Influenced

a phase II randomized study

DM Hyams, C de Oliveira, +8 authors cancer Chan A Cediranib in combination with fulvestrant i breast
Cancer Res 69(24 Suppl 3):abst 204 1970 Invest New Drugs • 2012
View 1 Excerpt

Anti-proliferative activity of c-src kinase inhibitor saracatinib correlates with IGF1R and EGFR expression in ovarian cancer cell lines

BA Helfrich, A Conner, C Conageski, K Behbakht, Spillman
Gynecol Oncol • 2010

Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo

JM Jürgensmeier, J Kendrew, +10 authors SR Wedge
Proc Am Assoc Cancer Res • 2010
View 1 Excerpt

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2010
View 1 Excerpt

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC)

JV Heymach, B Glisson, +5 authors DR Camidge
J Clin Oncol • 2010

Treatment profile of saracatinib (AZD0530) in combination with chemotherapy in patients with advanced ovarian carcinoma (OC)

LY Han, S Aamdal, +7 authors SB Kaye
Gynecol Oncol • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…